Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Yu Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8962-0975; OpenAlex author ID A5043161321. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 2 papers

Papers 4

  1. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-022-00429-3↗
  2. Pyroptosis regulators exert crucial functions in prognosis, progression and immune microenvironment of pancreatic adenocarcinoma: a bioinformatic and in vitro … Co-author DOI 10.1080/21655979.2021.2019873↗
  3. Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcp.29255↗
  4. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. Co-author DOI 10.1016/j.lfs.2020.118148↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jing Qian · 2 shared papers, 2020 · strength 0.23
  2. Fangshi Xu · 1 shared paper, 2022 · strength 0.17
  3. Honghong Pei · 1 shared paper, 2022 · strength 0.17
  4. Zhenghai Bai · 1 shared paper, 2022 · strength 0.17
  5. Jianbo Ma · 1 shared paper, 2020 · strength 0.13
  6. Yong Kwon Han · 1 shared paper, 2020 · strength 0.13
  7. Yan Wang · 1 shared paper, 2020 · strength 0.13
  8. Zhenkun Lou · 1 shared paper, 2022 · strength 0.10
  9. Kaixiong Tao · 1 shared paper, 2022 · strength 0.10
  10. Min Deng · 1 shared paper, 2022 · strength 0.10
  11. Zhijie Xu · 1 shared paper, 2022 · strength 0.10
  12. Xiangyu Zeng · 1 shared paper, 2022 · strength 0.10
  13. Xinyi Tu · 1 shared paper, 2022 · strength 0.10
  14. Ninghua Yao · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.